Recently, c-kit mutations have been reported as a novel adverse prognostic factor of acute myeloid leukemia with t(8;21)(q22;q22) translocation (t(8;21) AML). However, much remains unclear about its clinical significance. In this study, we developed a highly sensitive mutation detection method known as mutation-biased PCR (MB-PCR) and investigated the relationship between c-kit mutations and prognosis. When c-kit mutations were analyzed for 26 cases of t(8;21) AML using the direct sequence (DS) and MB-PCR, the latter had a much higher detection rate of c-kit mutations at initial presentation (DS 5/26(19.2%) vs MB-PCR 12/26(46.2%)). Interestingly for the three cases, in which c-kit mutations were observed only at relapse with the DS, c-kit mutations were detected at initial presentation using the MB-PCR. This result suggests that a minor leukemia clone with c-kit mutations have resistance to treatment and are involved in relapse. In univariate analyses, the presence of a c-kit mutation using DS was not an adverse prognostic factor (P ¼ 0.355), but was a factor when using MB-PCR (P ¼ 0.014). The presence of c-kit mutations with MB-PCR was also an independent adverse prognostic factor by multivariate analyses (P ¼ 0.006). We conclude that sensitivity of c-kit mutation detection method is important to predict prognosis for t(8;21) AML.
Introduction
Acute myeloid leukemia (AML) has the highest incidence among adult leukemia and includes a variety of subtypes with varying pathology, responsiveness to treatment and prognoses.
1,2 AML with the t(8;21)(q22;q22) translocation (t(8;21) AML), constitutes about 10% of all AMLs and has been considered an AML group with favorable prognosis based on its positive responsiveness to chemotherapy and high rate of complete remission. [3] [4] [5] Many studies have reported that when high-dose Ara-C is used as postremission therapy for t(8;21) AML, prognosis is good with overall disease-free survival rates of 50-70%. [6] [7] [8] [9] [10] [11] However, although t(8;21) AML has good prognosis overall, about 40% of cases relapse, of which half become treatment resistant. In fact, reports suggest that the prognosis of t(8;21) AML following first relapse is just as poor as other relapsed AMLs even when stem cell transplantation (SCT) is performed. [12] [13] [14] [15] Stratifying prognoses for t(8;21) AML become critical when determining, for example, SCT indications during the initial remission period. The white blood cell (WBC) count at initial examination, 12 WBC index, 16, 17 additional chromosomal aberrations such as del (9) 18 and loss of sex chromosomes and CD56 positivity 19 have been reported as adverse prognostic factors of t(8;21) AML. In recent years, c-kit mutations have also been proposed as a novel marker. 20, 21 The c-kit gene is located on chromosome 4q11-12 and encodes a 145 kD type III receptor tyrosine kinase. It has five extracellular immunoglobulin-like domains, a juxtamembrane domain and an intracellular kinase domain. c-kit mutations have been found in gastrointestinal stromal tumors (70% or more), mastocytosis (90% or more) and germ cell tumors (about 10%). 22, 23 In addition, they have been reported in B12-25% of cases of core-binding factor (CBF)-AMLs such as inv(16)(p13q22) and t(8;21) AML. 24 Normal c-kit sends proliferative cues into cells following stimulation by its ligand, stem cell factor and has an important role in early hematopoiesis. 25 On the other hand, mutant c-kit send proliferative signals into cells in a ligand-independent manner, and are considered class I aberrations, which have a role in leukemic cell proliferation. 26 In recent years, it has been reported that CBF-AML cases with c-kit mutations show a high rate of relapse and poor prognosis. 20, 21, [27] [28] [29] Reflecting these reports, the National Comprehensive Cancer Network's (NCCN) 2009 guidelines considered t(8;21) AML with c-kit mutations to be an intermediate prognosis group. However, at present, much remains unclear about the significance of c-kit mutations as a prognostic factor for CBF-AML. For example, in inv(16)(p13q22) AML, prognosis of patients with or without mutation in c-kit exon 8 is not significantly different. 21 Recently it is also reported that prognosis of pediatric CBF-AML patients with or without c-kit mutations is not significantly different. 30 The sensitivity of the detection method may be one reason why c-kit mutations remain an unclear prognostic factor for t(8;21) AML. A large majority of t(8;21) AML cases is classified as M2 by the French-American-British (FAB) Classification. Depending on the case, the proportion of leukemic cells may be less than 50%. In addition, nearly all c-kit mutations are heterozygous. It is possible that leukemic cells with c-kit mutations are quantitatively small populations at initial presentation and hence, not detectable with the direct sequence (DS) method. If the minor leukemic cells with c-kit mutations at initial presentation become treatment resistant and are involved in relapse, then a highly sensitive method to detect c-kit mutations is necessary in order to clarify the significance of c-kit mutations as a prognostic factor. Therefore, we used a highly sensitive mutation detection method known as mutation-biased PCR (MB-PCR) to detect c-kit mutations and investigated their significance as a prognostic factor for t(8;21) AML.
Patients and methods

Patient samples
We retrospectively analyzed 26 cases of t(8;21) AML treated at the Nippon Medical School and its affiliated facilities between January 1991 and January 2009. A search for c-kit mutations and Fms-like tyrosine kinase 3 internal tandem duplications (Flt3 ITD) was carried out on 26 initial diagnosis and 15 relapse cases where bone marrow or peripheral blood samples, in which 30% or more of the blast cells were available for use. Informed consents were obtained from the patients for genetic testing. This protocol was approved by our institutional review board.
Mutation analysis for c-kit and Flt3 ITD
Mononuclear cells from bone marrow or peripheral blood were isolated by density gradient centrifugation using lymphocyte separation medium (Organon, Durham, NC, USA). Genomic DNA of mononuclear cells was extracted with the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). PCR amplification of c-kit and Flt3 ITD was performed as previously described. 31, 32 Mutational analysis of the extracellular domain (exons 8 and 9), transmembrane domain (exon 10), juxtamembrane domain (exon 11) and the second intracellular kinase (TK) 2 domain (exons 17 and 18) of the c-kit gene was carried out with PCR followed by direct sequencing. Specific sequences of primers used for PCR and sequencing are available on request. To validate sequencing results, PCR products were inserted into the pCR2.1-TOPO vector using a TOPO TA cloning kit (Invitrogen, Carlsbad, CA, USA). Recombinant plasmids isolated from 8 to 12 white colonies were sequenced.
MB-PCR for c-kit mutations using QProbe
Quenching probe (QProbe) is a fluorescent probe in that a fluorescent substance is bound to cytosine on the terminal portion of the probe, which becomes quenched on hybridization with a complementary strand. With increasing temperature, the duplex unravels at a temperature (Tm) related to the strength of the bond between the QProbe and the complementary chain, at which point the fluorescence intensity recovers. Tm analysis is a technique to determine the degree of complementation between the QProbe and target nucleic acid by measuring the change in fluorescence intensity with increasing temperature. 33, 34 Here, we detected c-kit mutations using the QProbe method and a prototype of i-densy, a fully automated single nucleotide polymorphism genotyping systems. 34 Amplification was performed with MB-PCR for high-sensitivity detection of mutations using probes that perfectly matched the mutated form. In MB-PCR, the 3 0 terminal region of the primer is established as the mutation site, and allele-specific primers for wild-type and mutant primers are used for amplification. By adjusting the length of the primer, we devised a means by which the mutant form could be amplified more than the wild-type form. Furthermore, given the correlation between the proportion of the mutant form and the value of the fluorescence intensity detected by QProbe, it is possible to semiquantify the amount of mutations.
For sensitivity analysis, normal cells and clinical samples with heterozygous mutations were mixed and detection sensitivity was assessed. The ratio of each mutation was controlled by adjusting the ratio of blast cells from the clinical samples. Detection sensitivity was also assessed using a mixture of DNA from a normal subject and c-kit mutations containing fragment generated by PCR and TA cloning from clinical samples.
Statistical analysis
Patient characteristics were compared using Chi-square, Fisher and t tests. In addition, we analyzed the cumulative incidence of relapse (CIR) using the Kaplan-Meier log-rank test. Prognostic factors for t(8;21) AML were analyzed with multivariate analyses using Cox proportional hazards. In order to extract independent events, those events with a P-value of 0.20 or less were analyzed using the backward stepwise model selection procedure. Statistical analyses were carried out using SPSS software (version 12.1.4; SPSS Inc., Chicago, IL, USA).
Results
Clinical characteristics of patients with t(8;21) AML
The clinical characteristics of patients are shown in Table 1 . The median age was 50.3 years (range, 31-72 years) with 69.2% being males. Patients were followed-up for 3-112 months after initial presentation, with a median of 34.5 months. Of the 26 total t(8;21) AML cases, 15 (57.7%) relapsed.
Behenoyl cytosine arabinoside (BHAC)-DM-based, DNR/Ara-C and IDA/Ara-C regimens were used as induction therapies for 16, 7 and 3 cases, respectively. BHAC-DM-based regimen was a response-oriented individualized chemotherapy regimen using BHAC, dounorbicin (DNR) and 6-mercaptppurine (6-MP). [35] [36] [37] [38] All patients obtained complete remission by induction therapies. For post-remission consolidation, BHAC-based and HDACbased regimens were administered in 14 and 12 cases, respectively. As t(8;21) AML was considered to have favorable prognosis, SCT was not given in any of the cases during the first remission period.
Evaluation of post-remission course revealed a range of 1-64 months until first relapse (median 16 months) and CIR of 45.2% at 1 year and 58.6% at 6 years. We further analyzed the impact of post-remission therapy, WBC counts at initial examination, WBC index and CD56 expression on relapse. However, post-remission therapies, initial WBC counts, WBC index and CD56 expression were not significantly associated with relapse, and therefore, remain of unclear prognostic significance. Specifically, BHACbased regimen had CIR of 31.9% at 1 year and 48.9% at 6 years, whereas HDAC-based regimen resulted in CIR of 58.3% at 1 year and 66.7% at 6 years (P ¼ 0.384). When initial WBC counts were equal to or greater than 20 000/ml, CIR was 60.0% at 1 year and 80.0% at 6 years. When initial WBC counts were less than 20 000/ml, CIR was 36.2% at 1 year and 48.4% at 6 years (P ¼ 0.4343). WBC index were equal to or greater than 20, CIR was 43.2% at 1 year and 54.1% at 6 years. When WBC index were less than 20, CIR was 33.3% at 1 year and 66.7% at 6 years (P ¼ 0.7569). CD56 expression less than 10% was associated with CIR of 25.0% at 1 year and 52.4% at 6 years, whereas CD56 expression greater or equal to 10% resulted in CIR of 57.7% at 1 years and 66.2% at 6 years (P ¼ 0.083).
Comparison of chromosome analysis at initial presentation and at relapse
There were 14/26 cases (53.8%), in which a chromosomal aberration other than t(8;21)(q22;q22) was observed at initial presentation (Table 2) . Among these, the most frequent was the c-kit mutation detection sensitivity in t(8;21)AML S Wakita et al loss of a sex chromosome, which was observed in 12 cases (46.2%) (ÀY: 11 cases, ÀX: 1 case) ( Table 2) . Of 15 relapsed cases, three were unacceptable for chromosomal analyses. Additional chromosomal aberrations were observed at relapse in 10/12 cases (83.3%), which was higher relative to the rate at initial presentation. New chromosomal aberrations were observed in 9/12 cases (75%). Furthermore, most of these cases were observed with two or more chromosomal aberrations in addition to t(8;21)(q22;q22). This suggests greater chromosomal instability at relapse compared with initial presentation. However, prognostic analyses did not show a significantly higher relapse rate (RR) for cases with additional chromosomal aberrations at initial examination (P ¼ 0.400). Specifically, cases with additional chromosomal aberrations at initial examination had CIR of 30.4% at 1 year and 53.6% at 6 years, whereas those without additional chromosomal aberrations at initial examination had CIR of 63.3% at 1 year and 6 years.
c-kit mutations detected by direct sequence analysis
We screened for c-kit mutations using DS on 26 initial presentation cases and 13 relapsed cases with t(8;21) AML, other two relapsed cases were not available for analysis. In initial presentation subject samples, mutations were observed in 5/26 cases (19.2%; three cases of D816V and two cases of Abbreviations: AML, acute myeloid leukemia; CIR, cumulative incidence of relapse; WBC, white blood cell.
c-kit mutation detection sensitivity in t(8;21)AML S Wakita et al N822K). In relapsed subject samples, mutations were observed in 7/15 cases (46.7%; five cases of D816V and two cases of N822K, two cases were not acceptable). All c-kit mutations localized to the A-loop of exon 17. Intriguingly, of the relapsed cases with c-kit mutations, three cases (two cases of D816V and one case of N822K) were not detected c-kit mutation at initial presentation. Sequences of the detected c-kit mutations were D816V (GAT-GTC) and N822K (AAT-AAG). In addition to the above-mentioned mutations, we observed three cases of M541L (ATG-CTG; 11.5%), one case of K546K (AAA-AAG; 3.8%), and one case of L862L (CTG-CTC; 3.8%) as genetic polymorphisms (Table 2) . 
Establishment of a highly sensitive c-kit mutation detection method with MB-PCR
There were three cases, in which c-kit mutations were observed only at relapse using DS. For this reason, we surmised that minor clone of leukemic cells with c-kit mutations at initial presentation had resistance to treatment and became involved in relapse.
To prove this hypothesis, we established a highly sensitive method for detecting these c-kit mutations called MB-PCR. The c-kit mutation detection sensitivity in t(8;21)AML S Wakita et al sensitivity of detecting mutations using this method was tested by mixing cells containing D816V or N822K mutations with normal cells, which showed detection sensitivities of around 0.1% for D816V and 3.0% for N822K. Sensitivity analysis with a D816V-and N882K-containing fragment mixed with DNA from normal subjects produced a detection sensitivity of around 0.1% for both D816V and N822K. In contrast, the same sample subjected to the DS method resulted in a detection sensitivity of 10-30% for D816V and 30% for N822K. These results suggest that compared with the DS method, MB-PCR can detect mutations with much higher sensitivity (Figure 1 ).
Screening for c-kit mutations using highly sensitive mutation detection methods
When c-kit mutations of D816V and N822K were screened using MB-PCR, 12/26 of initial presentation samples were positive (46.2%; 4 cases of D816V and 8 cases of N822K). In 15 of relapse samples, two of them were not available for analyses, and seven of them were detected c-kit mutations (46.7%; five cases of D816V and two cases of N822K). In other words, MB-PCR offered a higher detection rate for c-kit mutations at initial presentation samples compared with DS. MB-PCR was able to detect c-kit mutations at initial presentation or early stage for the three cases, in which c-kit mutations were observed only at relapse using DS. MB-PCR could detect c-kit mutations at initial presentation of case number 4 and 8, as well as at the first relapse of case number 5, for which c-kit mutations could not detected using DS (Figure 2) .
Although less prevalent than the D816V and N822K mutations, there has been reports of small deletion-type mutation in the T417-D419 region of exon 8 in c-kit (i.e., del419, del418-419 and Thr417Ile/del418-419). In order to analyze this exon 8 mutation, we generated a QProbe (QProbe T417ÀD419 ) directed at the wild-type sequence. However, the T417-D419 deletion could not be detected in first presentation and relapsed t(8;21) AML samples.
Clinical significance of c-kit D816V and N822K mutations
The clinical progression of the 11 cases with detected c-kit mutations are shown in Figure 3 (one case was not included due to a short observation period). Five cases with the D816V observed at initial presentation using the MB-PCR method all eventually relapsed, and at relapse D816V remained positive in all cases (Figure 3) . For cases number 4 and 5 in particular, a low number of leukemic cells had D816V at initial presentation, which apparently became treatment resistant and amplified in subsequent relapse. Of the seven cases with N822K at initial presentation, six cases (86%) relapsed. Among these, however, N822K was observed in only two cases (33.3%) at relapse (Figure 3) .
Significance of c-kit mutation as a prognostic factor in t(8;21) AML Using DS and MB-PCR, we examined whether initial possession of a c-kit mutation has prognostic significance given the above MB-PCR results. No significant differences were found in clinical characteristics of case samples analyzed by both methods between those with or without c-kit mutations (Table 1 and Supplementary Table 1 ). By DS, there was a tendency for high RRs in the c-kit mutation ( þ ) group, but this was not statistically significant (Figure 4a) . Specifically, the c-kit mutation ( þ ) group had a RR of 80.0% and CIR of 60.0% at 1 year and 80.0% at 6 years, while the c-kit mutation (À) group had a RR of 52.4% and CIR of 35.7% at 1 year and 52.8% at 6 years (P ¼ 0.355). However, with MB-PCR, the c-kit mutation ( þ ) group had a statistically significant higher RR (Figure 4b) . Specifically, the c-kit mutation ( þ ) group had a RR of 83.3% and CIR of 72.5% at 1 year and 81.7% at 6 years, whereas the c-kit mutation (À) group had a RR of 35.7% and CIR of 22.1% at 1 year and 34.4% at 6 years (P ¼ 0.014).
Significance of c-kit mutation and Flt3ITD as a prognostic factor in t(8;21) AML Flt3 ITD is observed in about 25% of all AMLs and is one of the gene mutations considered to be an adverse prognostic factor. However, among the 26 cases of t(8;21) AML examined, Flt3 ITD was observed in only 2/26 (7.7%) cases at initial presentation, which is a lower incidence relative to c-kit mutations. In one case, Flt3 ITD and c-kit mutations were observed simultaneously. All patients with Flt3 ITD demonstrated relapse after short remission period. Considering the Flt3 ITD ( þ ) cases and/or MB-PCR c-kit mutation ( þ ) cases together as the mutation ( þ ) group, its relapse rate was shown to be significantly higher compared with those lacking both mutations (mutation (À) group: RR 30.8%, 1 year CIR 15.4%, 6 year CIR 34.2% versus mutation ( þ ) group: RR 84.6%, 1 year CIR 74.8%, 6 year CIR 83.2%, P ¼ 0.005) (Figure 4c ). c-kit mutation detection sensitivity in t(8;21)AML S Wakita et al
Multivariate analyses
We carried out multivariate analyses with the backward stepwise model selection procedure on age (^60 or o60 years old), gender (male or female), additional chromosomal aberrations (yes or no), WBC count at initial examination (^20 000/ml or o20 000/ml), hemoglobin (^10.0g/dl or o10.0g/dl), and post-remission therapy (BHAC-based or HDAC-based) in order to establish the significance of c-kit mutations as prognostic factors for relapse of t(8;21)AML. As a result, c-kit mutations and hemoglobin level at initial presentation were extracted as independent events by the backward stepwise model selection. Multivariate analyses with Cox proportional hazards revealed that MB-PCR detection of c-kit mutations (hazard ratio 5.074, P ¼ 0.006, 95%CI:
1.609À16.003) and c-kit mutation and/or Flt3 ITD (hazard ratio 6.650, P ¼ 0.003, 95%CI: 1.948À22.695) were independent adverse prognostic factors. On the other hand, multivariate analyses revealed that hemoglobin level at initial presentation were not independent adverse prognostic factors (P ¼ 0.11).
Discussion
We present MB-PCR as a highly sensitive method for detecting gene mutations and showed that cases for which c-kit mutations were observed only at relapse using DS actually already harbored those mutations at initial presentation at a low level undetectable by DS. In this investigation, although we did not Figure 3 Clinical courses of patients with c-kit mutations D816V and N822K. The top panel shows five cases, in which the D816V mutation was observed; the bottom panel shows six cases, in which the N822K mutation was observed. For cases 4 and 5 of D816V and case 8 of N822K, mutations were detected with MB-PCR at an earlier time point than with the DS method. All five cases with detected D816V relapsed, at which time the mutation could be detected even with the DS method. In contrast, among the six cases for which N822K was detected, long-term remission was obtained in one case with chemotherapy alone (number 6). For three cases (number 9, 10 and 11), the N822K mutation was detected at initial presentation but not at relapse. CR, complete remission; M, month; SCT, stem cell transplantation.
c-kit mutation detection sensitivity in t(8;21)AML S Wakita et al observe significant differences in relapse rates between cases with and without c-kit mutations using the DS method, we did observe a significant difference between cases with and without c-kit mutations using MB-PCR (Figures 4a and b) . From the above, we conclude that high sensitive method of detecting c-kit mutation, such as MB-PCR method, is important to predict prognosis for t(8;21) AML.
These results suggest that a minor leukemia clone with c-kit mutation at initial presentation has resistance to treatment and becomes involved in relapse. There have been several recent reports of the role of leukemic stem cells in relapse of leukemia. [39] [40] [41] [42] [43] [44] The rare c-kit mutation-harboring leukemic cells at initial presentation thought to be involved in relapse may represent leukemic stem cells with c-kit mutations. In the future, we plan to analyze c-kit mutations in leukemic stem cell fractions using MB-PCR.
Aberrant c-kit in t(8;21) AML has been reported in the extracellular domain of exon 8, the juxtamembrane domain of exons 10 and 11, and the A-loop domain with tyrosine kinase activity of exon 17. Some previous in vitro studies report that the D816V mutation confers higher tumor growth and antiapoptotic potential compared with mutations in the extracellular domain of exon 8 or in the juxtamembrane domains of exons 10 and 11. 45, 46 Similar observations have been reported for Flt3 mutations, which are class I mutations as found in c-kit. Specifically, mutations in the Flt3 tyrosine kinase domain (TKD) confer lower tumor growth and antiapoptotic potential compared with Flt3 ITD. 47, 48 These findings suggest that biological functions of c-kit mutations differ depending on the mutation site, which may affect responsiveness to treatments. In our study, we did not observe any mutations apart from D816V and N822K in the exon 17 A-loop. However, all cases with D816V at initial presentation eventually relapsed while preserving the D816V mutation. In contrast, only one of three cases with N822K at initial presentation were detected N822K at relapse. This result suggests that D816V and N822K may differ functionally, even if this mutation is also in the same A-loop. Thus, we believe that functional analysis of both mutations will be necessary.
Although rare, mutations other than D816V, N822K, and the small T417-D419 deletion have been reported for t(8;21) AML. However, we detected no mutations other than D816V and N822K by screening exons 8-11, 17 and 18 using the both MB-PCR and DS method in relapse samples. On the basis of this, we conclude that at least for the cases examined in our study, c-kit mutations other than D816V and N822K were not major for relapse. In the future, we hope to investigate more cases and determine the clinical significance of rare c-kit mutations. 20, 27, 49 This investigation showed that aberrant c-kit at initial presentation in t(8;21)AML is associated with a significantly higher rate of relapse and shorter period of first remission. However, aberrations of unknown gene are involved in t(8;21) AML based on the following observations: a class I aberration must additionally occur in chimeric protein AML1-ETO for t(8;21)AML mouse model onset, 50 ,51 c-kit mutations and Flt3 ITD are not observed in about 50% of t(8;21) AML, and there are cases in which the N822K mutation disappeared at relapse. In addition, given report of positive responsiveness to high-dose Ara-C therapy and favorable prognosis of t(8;21) AML with N-Ras mutations, which is also a class I mutation, 52 other class I mutations should also be examined.
Our results do not directly suggest that allogeneic SCT is indicated during the initial remission period for t(8;21) AML with c-kit mutations, as is the case with AML groups with poor prognosis. Recent reports have been inconclusive as to whether prognosis of t(8;21) AML after the first relapse is poor, like other relapsed AMLs, 15 or still favorable. 53 However, as these results c-kit mutation detection sensitivity in t(8;21)AML S Wakita et al
were not stratified according to c-kit mutations, it remains unclear whether allogeneic SCT is indicated during the first remission period for t(8;21) AML with c-kit mutations. In addition, we have previously shown the utility of SCT using autologous disease-free peripheral blood stem cells in the first remission period of t(8;21) AML, including cases of c-kit mutations at initial presentation. 31 This result is intriguing because it suggests that autologous peripheral blood stem cells without residual disease are useful against t(8;21) AML with c-kit mutations. Taking the above into consideration, future studies should investigate stratification of SCT indications during the first remission period according to genetic mutations such as ckit mutations and Flt3 ITD for t(8;21) AML, similar to current investigations for normal karyotype AML.
Finally, this is a retrospective study, and the number of patients examined was insufficient to carry out prognostic analysis. A large-scale prospective study is needed to clarify the utility of high-sensitivity analysis of c-kit mutations for t(8;21) AML in the clinical setting.
